reports
- Olfa Taamallah
- Yan Derocles
VLS VALNEVA SE
ELG ELMOS SEMICONDUCTOR SE
NOEJ NORMA GROUP SE
ELIS ELIS SA
SHA SCHAEFFLER AG
KRN KRONES AG
PSPN PSP SWISS PROPERTY AG
SIGHT GENSIGHT BIOLOGICS SA
BEZ BERENTZEN GRUPPE
ASS APPLUS SERVICES S.A.
COFA COFACE SA
JUN3 JUNGHEINRICH AG PREF
IDR INDRA SISTEMAS S.A. CLASS A
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Olfa Taamallah
- Yan Derocles
VLS VALNEVA SE
ELG ELMOS SEMICONDUCTOR SE
NOEJ NORMA GROUP SE
ELIS ELIS SA
SHA SCHAEFFLER AG
KRN KRONES AG
PSPN PSP SWISS PROPERTY AG
SIGHT GENSIGHT BIOLOGICS SA
BEZ BERENTZEN GRUPPE
ASS APPLUS SERVICES S.A.
COFA COFACE SA
JUN3 JUNGHEINRICH AG PREF
IDR INDRA SISTEMAS S.A. CLASS A
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Damien Choplain
- Martial Descoutures
Valneva : Disappointing Q1 due to supply constraints – guidance confir...
>Top and bottom line below expectations - Q1 revenues came in 2% lower at € 32.8m (-24% vs cs) with product sales stable at € 32.1m (-21% vs cs). This disappointing performance can mainly be attributed to supply issue for Ixiaro which showed a decline of 5% (-34% vs cs). Dukoral saw sales grow by 10% to € 11.3m (+18% vs cs) underpinned by a recovery in the traveller market. As expected, third-party distribution (-9%, -33% vs Cs) suffered from supply constraints for t...
- Oscar Haffen Lamm
Valneva: reports Q1, full year guidance reiterated
Valneva reported its Q1 2024 results where revenues came in at EUR 32.8m (vs css EUR 43.1m), including product sales of EUR 32.1m, driven by Ixiaro (EUR 16.6m, -4.8%), Dukoral (EUR 11.3m, +10.3%), and third party products (EUR 4.1m, -8.9%). The decrease in Ixiaro sales is mainly attributed by the s
- Damien Choplain
- Martial Descoutures
Valneva : T1 décevant lié à des contraintes d’approvisionnement – Guid...
>En dessous de attentes en topline et bottom line - Les revenus T1 sont en baisse de 2% à 32.8 M€ (-24% vs css) avec des ventes de produits stables à 32.1 M€ (-21% vs css). Cette performance décevante s’explique principalement par des problèmes d'approvisionnement sur Ixiaro qui ressort en baisse de 5% (-34% vs css). Dukoral affiche une croissance de 10% à 11.3 M€ (+18% vs css) soutenue par la reprise du marché du voyageur. Comme prévu, la distribution pour tiers (-9%...
Valneva Reports First Quarter 2024 Financial Results and Provides Cor...
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidance Cash position of €176.6 million, including €95 million from sale of Priority Review Voucher (PRV)1. Significantly extended cash runway with recent update of debt financing agreement2Substantially lower cash burn expected in 2024 as Valneva expects to complete...
Valneva publie ses résultats financiers du premier trimestre 2024 et f...
Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Principaux éléments financiers du premier trimestre Chiffre d’affaires total de 32,8 millions d’euros dont 32,1 millions d’euros de ventes de produits, en ligne avec les prévisions pour l'exercice 2024Position de trésorerie de 176,6 millions d’euros dont 95 millions d’euros provenant de la vente du bon de revue prioritaire (PRV)1. Extension significative de la visibilité financière ...
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE VALNEVA Declaration of shares and voting rights April 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 6, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change D...
Declaration of voting rights - Valneva SE, March 2024
Declaration of voting rights - Valneva SE, March 2024 VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting right...
Déclaration d'actions et de droits de vote de la société Valneva SE - ...
Déclaration d'actions et de droits de vote de la société Valneva SE - mars 2024 VALNEVA Déclaration d’actions et de droits de vote 31 mars 2024__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 4 avril 2024 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droi...
- Oscar Haffen Lamm
VALNEVA: Initiates phase 1 trial of the Zika vaccine candidate
Valneva announced the initiation of the phase 1 trial of the Zika vaccine candidate (VLA1601), its 2nd generation adjuvanted inactivated vaccine, which will investigate its safety and immunogenicity. The phase 1 will enroll approx. 150 participants (18-49 years old) in the US who will receive a low
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Cand...
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate Saint-Herblain (France), March 26, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is included in the Food and Dru...
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième ...
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika Saint-Herblain (France), le 26 mars 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui l’initiation d’un essai de Phase 1 pour évaluer l’innocuité et l’immunogénicité de VLA1601, son candidat vaccin inactivé et adjuvanté de deuxième génération contre le virus Zika (ZIKV). Il n'existe pas de vaccins préventifs ni de traitements efficaces contre le virus Zika qui demeure donc une menace pour la santé publique et a été inclus dans le pro...
Valneva Announces Filing of 2023 Universal Registration Document and U...
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F Saint-Herblain (France), March 25, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023 Annual Financial Report, the Compan...
Valneva annonce le dépôt de son Document d’Enregistrement Universel 20...
Valneva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son rapport annuel américain « Form 20-F » Saint-Herblain (France), 25 mars 2024 – (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui le dépôt, le 22 mars 2024, de son Document d’enregistrement universel 2023 auprès de l’Autorité des Marchés Financiers (AMF) sous le numéro D.24-0157, et de son rapport annuel « Form 20-F » auprès de la Securities and Exchange Commission (SEC) aux Etats-Unis. Le Document d’enregistrement universel 2023 de Valneva – disponible dans s...
- Oscar Haffen Lamm
Valneva: Model Update
Post-FY23 earnings publication on the 20th March, we have updated our model with an unchanged BUY rating and PT at EUR 9. We adjusted our estimates for product sales taking into account the upgraded guidance for 2024 and the mid-term outlook provided by the company, namely i) Ixiaro guided continue
Valneva fera une présentation sur son vaccin contre le chikungunya, IX...
Valneva fera une présentation sur son vaccin contre le chikungunya, IXCHIQ®, et participera à plusieurs événements lors du 24ème World Vaccine Congress à Washington, D.C. Saint-Herblain (France), le 21 mars 2024 – (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’elle fera une présentation sur son vaccin à injection unique contre le chikungunya, IXCHIQ®, animera une table ronde sur les virus Zika et chikungunya, et participera à un débat sur les efforts d'éradication du chikungunya lors du 24ème World Vaccine Congress, qui se tiendra du 1...
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in ...
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. Saint-Herblain (France), March 21, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ®, moderate a roundtable on the Zika and chikungunya viruses, and participate in a panel discussion on efforts to eradicate chikungunya at the 24th World Vaccine Congress, which will take place between April 1-4, 2024 at the Walter E. Washington convention center in Was...
- Fehmi Ben Naamane
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 03/20/2024
We are upgrading the energy sector to Overweight vs Neutral (excluding Oil Services, already on Overweight). The recent rebound in oil prices is set to continue, driven by short, medium and long-term factors: value, cyclical, little debt and good shareholder returns. Technical analysis reveals a strong trend that is only just beginning. GALP enters our Large Caps list; CellNex exits it. - ...
WTB WHITBREAD PLC
EURN EURONAV NV
CEN GROUPE CRIT SA
BEN BENETEAU SA
VIRP VIRBAC SA
VLS VALNEVA SE
PIG HAULOTTE GROUP SA
ISP INTESA SANPAOLO S.P.A.
DEQ DEUTSCHE EUROSHOP AG
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
ALVIV VISIATIV SA
UCG UNICREDIT S.P.A.
SHOT SCANDIC HOTELS GROUP
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
COPN COSMO PHARMACEUTICALS NV
PWG PRODWAYS GROUP SA
IHG INTERCONTINENTAL HOTELS GROUP PLC
CABKA CABKA N.V.
- Damien Choplain
- Martial Descoutures
Valneva : Announcement of an attractive medium-term outlook
>Adjusted EBITDA better than expected - Adjusted EBITDA came to -€ 65m, above the consensus at -€ 72m. We retain: 1/ total sales (already reported) down 57% y-o-y at € 154m, impacted by an unfavourable base effect as 2022 included € 280m in revenues related to the Covid vaccine supply agreement (product sales are up 26% and 63% excluding Covid vaccines); 2/ a total gross margin for product sales stable at 46% vs 45.5% in 2022, but down for Ixiaro (52% vs 62% in 2022)...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.